Fate Therapeutics Inc. (FATE) Insider Purchases $99,997.38 in Stock
Fate Therapeutics Inc. (NASDAQ:FATE) insider Chris Storgard acquired 37,593 shares of Fate Therapeutics stock in a transaction that occurred on Wednesday, November 23rd. The stock was bought at an average cost of $2.66 per share, with a total value of $99,997.38. Following the acquisition, the insider now directly owns 9,090 shares of the company’s stock, valued at $24,179.40. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of Fate Therapeutics Inc. (NASDAQ:FATE) opened at 2.94 on Thursday. The firm’s 50-day moving average price is $2.51 and its 200 day moving average price is $2.28. Fate Therapeutics Inc. has a 12-month low of $1.46 and a 12-month high of $4.67. The firm’s market cap is $100.40 million.
Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.02. Fate Therapeutics had a negative return on equity of 112.48% and a negative net margin of 740.69%. On average, equities analysts expect that Fate Therapeutics Inc. will post ($1.14) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Fate Therapeutics Inc. (FATE) Insider Purchases $99,997.38 in Stock” was posted by Daily Political and is owned by of Daily Political. If you are reading this article on another website, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this article can be read at http://www.dailypolitical.com/2016/12/01/fate-therapeutics-inc-fate-insider-purchases-99997-38-in-stock.html.
Several equities research analysts recently weighed in on the stock. Wedbush reduced their price objective on shares of Fate Therapeutics from $8.00 to $7.00 and set an “outperform” rating for the company in a report on Tuesday, November 8th. BMO Capital Markets set a $4.00 price objective on shares of Fate Therapeutics and gave the stock a “buy” rating in a report on Monday, August 8th. Zacks Investment Research cut shares of Fate Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 11th. HC Wainwright reiterated a “buy” rating on shares of Fate Therapeutics in a research report on Tuesday, August 9th. Finally, Roth Capital began coverage on shares of Fate Therapeutics in a research report on Thursday, September 22nd. They issued a “buy” rating and a $8.00 price target on the stock. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Fate Therapeutics has a consensus rating of “Buy” and a consensus price target of $5.79.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Board of Trustees of The Leland Stanford Junior University bought a new position in Fate Therapeutics during the second quarter valued at about $495,000. Jacobs Levy Equity Management Inc. raised its position in Fate Therapeutics by 448.8% in the first quarter. Jacobs Levy Equity Management Inc. now owns 204,447 shares of the biopharmaceutical company’s stock valued at $368,000 after buying an additional 167,194 shares in the last quarter. Emerald Acquisition Ltd. bought a new position in Fate Therapeutics during the second quarter valued at about $137,000. Vanguard Group Inc. raised its position in Fate Therapeutics by 3.5% in the second quarter. Vanguard Group Inc. now owns 657,573 shares of the biopharmaceutical company’s stock valued at $1,118,000 after buying an additional 22,098 shares in the last quarter. Finally, BlackRock Fund Advisors raised its position in Fate Therapeutics by 26.2% in the second quarter. BlackRock Fund Advisors now owns 75,572 shares of the biopharmaceutical company’s stock valued at $128,000 after buying an additional 15,701 shares in the last quarter. Hedge funds and other institutional investors own 57.07% of the company’s stock.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.